Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Nov 14:2014:1294-301.
eCollection 2014.

A Comparison of Data Driven-based Measures of Adherence to Oral Hypoglycemic Agents in Medicaid Patients

Vivienne J Zhu  1 , Wanzhu Tu  1 , Marc B Rosenman  1 , J Marc Overhage  2
Affiliations
Comparative Study

A Comparison of Data Driven-based Measures of Adherence to Oral Hypoglycemic Agents in Medicaid Patients

Vivienne J Zhu et al. AMIA Annu Symp Proc. .

Abstract

We evaluated and compared different methods for measuring adherence to Oral Antihyperglycemic Agents (OHA), based on the correlation between these measures and glycated hemoglobin A1C (HbA1c) levels in Medicaid patients with Type 2 diabetes. An observational sample of 831 Medicaid patients with Type 2 diabetes who had HbA1c test results recorded between January 1, 2001 and December 31, 2005 was identified in the Indiana Network of Patient Care (INPC). OHA adherence was measured by medication possession ratio (MPR), proportion of days covered (PDC), and the number of gaps (GAP) for 3, 6, and 12-month intervals prior to the HbA1c test date. All three OHA adherence measurements showed consistent and significant correlation with HbA1c level. The 6-month PDC showed the strongest association with HbA1c levels in both unadjusted (-1.07, P<0.0001) and adjusted (-1.12, P<0.0001) models.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
An example of calculating MPR, PDC and GAP.
See this image and copyright information in PMC

References

    1. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and Economic Consequences of Medication Adherence in Diabetes: A Systematic Literature Review. Manag Care Interface. 2006 Jul;19(7):31–41. - PubMed
    1. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009 Jun 16;119(23):3028–35. - PubMed
    1. Egede LE, Gebregziabher M, Dismuke CE, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012 Dec;35(12):2533–9. - PMC - PubMed
    1. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5A):27S–34S. - PubMed
    1. World Health Origanization Adherence to Long-term therapies: Evidence for action. 2003

Publication types